Novavax Inc

Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
www.novavax.com

Market Cap $923.79M
Debt $169.68M
Cash $545.29M
EV $548.19M
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$187.50M
EBIT	-$176.62M
ROA	-11%
Equity	-$623.84M
Growth Stability	1
PE	-4.93
PB	-1.48
P/S	1.35
Price/Cash	0.59
Debt/Equity	-0.27
Net Margins	-27%
Gross Margins	70%
Op. Margins	-26%
Sales Growth YoY	-70%
Sales Growth QoQ	4%
Sales CAGR	94%
FCF CAGR	0%
Equity CAGR	1%
Earnings Growth YoY	-55%
Earnings Growth QoQ	-33%

Sales CAGR 5Y	59%
FCF CAGR 5Y	2%
Equity CAGR 5Y	-0%
Earnings CAGR 3Y	-25%
Sales CAGR 3Y	-25%
Market Cap	$923.79M
Revenue	$682.16M
Assets	$1.56B
Total Debt	$169.68M
Cash	$545.29M
Shares Outstanding	152.19M
EV	548.19M
Working Capital	-25.47M
Current Ratio	0.98
Gross Profit	$479.42M
Shares Growth 3y	35%
Equity Growth QoQ	19%
Equity Growth YoY	-13%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

SEC Filings

Direct access to Novavax Inc (NVAX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Novavax Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Novavax Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Novavax Inc Discounted Cash Flow

Fully customizable DCF calculator online for Novavax Inc.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-433%	-2K%	-589%	-539%	-711%	-88%	-152%	-33%	-55%	-27%	-27%
ROA	-	-68%	-57%	-84%	-70%	-26%	-65%	-29%	-30%	-11%	-11%
ROE	-	5K%	181%	110%	71%	-67%	496%	104%	76%	30%	-

Bad Net Margins (-27.49%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-1.16	-2.22	-1.71	-2.32	-3.31	1.22	-	-	-	-
Debt over Equity	0	-57.04	-3.12	-1.9	-1.72	0.51	-0.92	-0.77	-0.23	-0.27	-0.27
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.27)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-58%	103%	10%	-46%	2K%	141%	73%	-50%	-31%	59%
Earnings YoY growth	-	78%	-34%	1%	-28%	215%	317%	-62%	-17%	-66%	-
Equity YoY growth	-	-102%	2K%	65%	11%	-437%	-156%	80%	13%	-13%	-0%
FCF YoY growth	-	90%	-48%	30%	-26%	-30%	-373%	-	-	-	2%